ACCC | FDA Approves Eltrombopag 25-mg Powder for Suspension Package Size
FDA Approves Eltrombopag 25-mg Powder for Suspension Package Size
Novartis Pharmaceuticals Corporation has announced that the US Food and Drug Administration approved Promacta® (eltrombopag) 25-mg powder for suspension package size on March 23, 2020.
In Person Conference & ConventionSeptember 22, 2026 at 5:00 PM CDT1500 Park Pl Blvd, Minneapolis, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, Minneapolis
